Neurodegenerative Disease Market Forecasted to Reach USD 83.37 Billion by 2030, Driven by Aging Populations and New Therapeutics

Mordor Intelligence has published a new report on the "Neurodegenerative Disease Market" offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The neurodegenerative disease market size is estimated at approximately USD 59.06 billion in 2025 and is expected to rise to around USD 83.37 billion by 2030, reflecting a compound annual growth rate of about 7.14 percent. This market includes treatments for disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Huntington's disease, and others. Key forces shaping growth include growing prevalence of age-related neurological disorders, improvements in diagnostic tools, regulatory support for disease-modifying therapies, and increased investment in research and development.

The neurodegenerative disease market analysis reveals several critical dimensions by which the industry is expanding: geography, drug class, molecule type, route of administration, and distribution channel. North America currently leads in market share, while Asia-Pacific is projected to grow at the fastest rate owing to both demographic changes and expanding healthcare access. The dynamic between traditional small-molecule drugs and newer biologics, gene & cell therapies, RNA-based approaches is shifting as the market responds to unmet needs and scientific progress.

Report Overview: https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market?utm_source=openpr

Key Trends in the Neurodegenerative Disease Market

Aging Populations and Rising Disease Burden
As populations around the world grow older, the incidence of neurodegenerative diseases increases markedly. Alzheimer's disease alone contributes a heavy share of cases, and prevalence increases more steeply with age. Health systems in many developed countries have begun incorporating dementia and similar disorders into national healthcare planning, which means more resources for early diagnosis and management. This trend supports growth in demand across therapeutic classes and diagnostics in the neurodegenerative disease market.

Emergence of Disease-Modifying Therapies
Treatment is shifting from symptom relief toward modifying the underlying disease in key indications. New approvals of agents that clear amyloid and target disease pathology more directly have changed how payers evaluate value. A number of anti-amyloid and anti-tau antibodies are in late-stage development, and there is growing interest in combination regimens that may slow disease progression. These developments are reshaping market-share dynamics, favoring newer mechanisms over traditional treatments.

Advancements in Diagnostics and Biomarkers
Better imaging techniques, fluid biomarkers (such as those detectable in cerebrospinal fluid or plasma), and other diagnostic tools are helping detect neurodegenerative disease earlier. Earlier detection allows interventions sooner in the disease course, potentially improving outcomes and enabling therapies to be more effective. As diagnostic infrastructure expands, particularly in more regions, this trend will further fuel growth in neurodegenerative disease market size.

Innovation in Molecule Types and Drug Classes
While small-molecule drugs still hold a large share of the market, RNA-based therapeutics, gene & cell therapies, and modern biologics are growing more quickly. Improvements in vector design, manufacturing, and delivery technologies are enabling these newer therapies to enter more advanced stages, adding diversity to drug class representation, and shifting some of the growth away from traditional classes such as cholinesterase inhibitors or dopamine agonists.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/neurodegenerative-disease-market?utm_source=openpr

Market Segmentation

The neurodegenerative disease market is divided into several segments, each showing unique patterns of growth. Below are the major segmentation categories and what they indicate:

By Indication

Alzheimer's disease is the leading indication in terms of revenue share, reflecting both high prevalence and development of new treatments.

ALS is among the fastest-growing indications, helped by gene-silencing and rare disease programs.

Other indications like Parkinson's disease, multiple sclerosis, Huntington's disease also contribute important shares, but with more mature competitive landscapes.

By Drug Class

Cholinesterase inhibitors still hold a large portion of market share among traditional classes.

Gene & cell therapies are forecast to grow at high rates, challenging the dominance of existing classes.

Monoclonal antibodies and immunomodulators also show strong momentum, especially as disease-modifying potential is demonstrated in clinical trials.

By Route of Administration

Oral remains the dominant mode, due to ease of use and patient preference.

Parenteral (intravenous, subcutaneous) routes are vital to deliver biologics and gene therapies.

Transdermal and intranasal delivery are growing faster as adherence, minimal invasiveness, and localized delivery become more valued.

By Distribution Channel

Hospital pharmacies continue to lead, especially for initiation of complex therapies, infusions, or therapies requiring specialized handling.

Retail and specialty pharmacies provide more routine access, especially for symptomatic therapies.

Online pharmacies (including digital channels and telemedicine) are showing rapid growth, offering delivery and convenience, particularly for maintenance therapy and in regions where physical access is more limited.

By Geography

North America holds the largest share of the neurodegenerative disease market due to regulatory systems, reimbursement, and high rates of diagnosis and treatment adoption.

Asia-Pacific is the fastest-growing region, spurred by aging populations, increasing healthcare spending, more regulatory capacity, and expanding diagnostic and treatment access.

Europe shows steady growth, with varied country-level dynamics around reimbursement, health technology assessment, and diagnostic infrastructure.

Explore Our Full Library of Healthcare Industry Research Reports

https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Key Players in the Neurodegenerative Disease Market

Major companies involved in this market include a mix of large pharmaceutical firms and smaller biotech or specialist players.

Boehringer Ingelheim International GmbH

UCB SA

Novartis AG

Merck & Co Inc.

Teva Pharmaceuticals, Inc.

Explore more insights on neurodegenerative disease market competitive landscape: https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market/companies?utm_source=openpr

Conclusion

The neurodegenerative disease market is set on a growth path where the neurodegenerative disease market size will broadly increase over the coming years as the neurodegenerative disease market share of newer therapies rises. Aging populations, greater diagnostic capacity, and the arrival of disease modifying therapies are among the strongest trends. While small-molecule treatments and symptom relief will remain important, the contribution from gene, cell, biologics, and RNA-based options is becoming more significant.

For complete market analysis, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market?utm_source=openpr

Industry Related Reports

Neurodegenerative Disease Diagnostics Market: The Neurodegenerative Disease Diagnostics Market Report is Segmented by Product Type (Imaging Diagnostics, In-Vitro Diagnostics, and More), Biomarker Type (Protein, Neurofilament Light Chain, Genetic, and Other Emerging Types), Application (Alzheimer's Disease, Andmore), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America).
Get More Insights: https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-diagnostics-market?utm_source=openpr

Nanozymes Market: The Nanozymes Market Report is Segmented Into Application (Diagnostic Medicine, Targeted Therapy, and Biosensing), Treatment Type (Cancer Therapy, Antibacterial Activity, Neurodegenerative Disease Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/nanozymes-market?utm_source=openpr

Nanomedicine Market: The Nanomedicine Market report segments the industry into Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases, Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America).
Get More Insights: https://www.mordorintelligence.com/industry-reports/healthcare-nanotechnology-nanomedicine-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.